Dr. Craig A. Witz, Reproductive Endocrinologist and Director of Clinical Research at Houston Fertility Institute, served as lead researcher of a study comparing the hormone medications Menopur (menotropins for injection) and rFSH (recombinant follicle stimulating hormone) in patients predicted to be high responders undergoing intracytoplasmic sperm injection (ICSI) with IVF. Dr. Witz partnered with Ferring Pharmaceuticals on the comparative clinical trial aimed at identifying how to provide individualized fertility treatment for a population that can be challenging to treat. The new clinical data is now published.
The randomized, assessor-blinded study, MEGASET-HR, involved a total 620 patients at multiple fertility centers. Results found that while Highly Purified Menotropin (HP-hMG) provided comparable efficacy to rFSH, patients in the Menopur treatment group experienced fewer adverse events, including pregnancy loss.
“The intriguing data from this study is the relationship between cumulative live birth rate and the number of transfers, early pregnancy loss and safety data,” says Dr. Witz. “As physicians, we are always looking for opportunities to personalize care for the patients that we see on a day-to-day basis and are excited about these results.”
Read the published study, Randomized, Assessor-Blinded Trial Comparing Highly Purified Human Menotropin and Recombinant Follicle-Stimulating Hormone in High Responders Undergoing Intracytoplasmic Sperm Injection.